Tatiana A. Giovannucci, Claire A. Leckey, John Coulton, Henrik Zetterberg, Donald L. Elbert, Randall J. Bateman, Kevin Mills, Selina Wray, Nupur Ghoshal, Chihiro Sato, Ross W. Paterson
{"title":"人脑脊液和脑组织中神经丝光的稳定同位素标记动力学（SILK）示踪","authors":"Tatiana A. Giovannucci, Claire A. Leckey, John Coulton, Henrik Zetterberg, Donald L. Elbert, Randall J. Bateman, Kevin Mills, Selina Wray, Nupur Ghoshal, Chihiro Sato, Ross W. Paterson","doi":"10.1002/alz.095735","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Neurofilament light protein (NfL) is a promising biomarker of neuronal injury and neurodegeneration. NfL levels in cerebrospinal fluid (CSF) and blood provide information about disease progression and are increasingly relied on as outcome measure in clinical trials. Understanding NfL kinetics <i>in vivo</i> is critical for interpreting NfL in response to new events where a steady state cannot be assumed, such as acute injury, disease onset or progression, or response to disease-modifying therapies.</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>We infused human participants with diagnosed primary tauopathies (progressive supranuclear palsy, n = 5; corticobasal syndrome, n = 3; behavioural variant frontotemporal dementia, n = 2) with a stable isotope tracer (<sup>13</sup>C<sub>6</sub>-leucine) and collected CSF by lumbar puncture at 4, 14, 20, 60 and 120 days post-labelling. In addition, <i>post-mortem</i> brain tissue from three participants who were infused with the tracer 18, 44 and 50 months earlier were homogenised and biochemically fractionated to separate the soluble and insoluble fraction. NfL was enriched in all samples via immunoprecipitation. The ratio of labelled to unlabelled NfL was measured monitoring proteotypic peptides using established targeted mass spectrometry workflows to quantitate the tracer-to-tracee ratio (TTR).</p>\n </section>\n \n <section>\n \n <h3> Result</h3>\n \n <p>Analysis of CSF detected low labelling of NfL (0.04 – 0.36% TTR) by 120 days that was comparable to the TTR levels detected in the soluble brain fraction. There was NfL present in the insoluble fraction (2.87% of the total NfL at 18-, 8.87% at 44- and 14.03% at 50-months <i>post-mortem</i>, averaged across several NfL peptides), with different relative abundances of NfL domains between these fractions. Interestingly, the <sup>13</sup>C<sub>6</sub>-labelled NfL signal detected in the insoluble fraction was more abundant, despite a higher recovery of total NfL in the soluble fraction.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>NfL turnover <i>in vivo</i> is remarkably slow as it is scarcely captured by 120 days post-labelling. The labelling results from brain tissue suggest that in these cases of primary tauopathies newly-synthesized NfL might be delocalized to a pool of protein of low solubility that does not contribute to NfL levels in CSF. Current experiments are addressing whether newly-synthesized NfL might be sequestered into pathological inclusions.</p>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"20 S8","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.095735","citationCount":"0","resultStr":"{\"title\":\"Stable Isotope Labelling Kinetics (SILK) tracing of neurofilament light in human cerebrospinal fluid and brain tissue\",\"authors\":\"Tatiana A. Giovannucci, Claire A. Leckey, John Coulton, Henrik Zetterberg, Donald L. Elbert, Randall J. Bateman, Kevin Mills, Selina Wray, Nupur Ghoshal, Chihiro Sato, Ross W. Paterson\",\"doi\":\"10.1002/alz.095735\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Neurofilament light protein (NfL) is a promising biomarker of neuronal injury and neurodegeneration. NfL levels in cerebrospinal fluid (CSF) and blood provide information about disease progression and are increasingly relied on as outcome measure in clinical trials. Understanding NfL kinetics <i>in vivo</i> is critical for interpreting NfL in response to new events where a steady state cannot be assumed, such as acute injury, disease onset or progression, or response to disease-modifying therapies.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Method</h3>\\n \\n <p>We infused human participants with diagnosed primary tauopathies (progressive supranuclear palsy, n = 5; corticobasal syndrome, n = 3; behavioural variant frontotemporal dementia, n = 2) with a stable isotope tracer (<sup>13</sup>C<sub>6</sub>-leucine) and collected CSF by lumbar puncture at 4, 14, 20, 60 and 120 days post-labelling. In addition, <i>post-mortem</i> brain tissue from three participants who were infused with the tracer 18, 44 and 50 months earlier were homogenised and biochemically fractionated to separate the soluble and insoluble fraction. NfL was enriched in all samples via immunoprecipitation. The ratio of labelled to unlabelled NfL was measured monitoring proteotypic peptides using established targeted mass spectrometry workflows to quantitate the tracer-to-tracee ratio (TTR).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Result</h3>\\n \\n <p>Analysis of CSF detected low labelling of NfL (0.04 – 0.36% TTR) by 120 days that was comparable to the TTR levels detected in the soluble brain fraction. There was NfL present in the insoluble fraction (2.87% of the total NfL at 18-, 8.87% at 44- and 14.03% at 50-months <i>post-mortem</i>, averaged across several NfL peptides), with different relative abundances of NfL domains between these fractions. Interestingly, the <sup>13</sup>C<sub>6</sub>-labelled NfL signal detected in the insoluble fraction was more abundant, despite a higher recovery of total NfL in the soluble fraction.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>NfL turnover <i>in vivo</i> is remarkably slow as it is scarcely captured by 120 days post-labelling. The labelling results from brain tissue suggest that in these cases of primary tauopathies newly-synthesized NfL might be delocalized to a pool of protein of low solubility that does not contribute to NfL levels in CSF. Current experiments are addressing whether newly-synthesized NfL might be sequestered into pathological inclusions.</p>\\n </section>\\n </div>\",\"PeriodicalId\":7471,\"journal\":{\"name\":\"Alzheimer's & Dementia\",\"volume\":\"20 S8\",\"pages\":\"\"},\"PeriodicalIF\":13.0000,\"publicationDate\":\"2025-01-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.095735\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's & Dementia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/alz.095735\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.095735","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Stable Isotope Labelling Kinetics (SILK) tracing of neurofilament light in human cerebrospinal fluid and brain tissue
Background
Neurofilament light protein (NfL) is a promising biomarker of neuronal injury and neurodegeneration. NfL levels in cerebrospinal fluid (CSF) and blood provide information about disease progression and are increasingly relied on as outcome measure in clinical trials. Understanding NfL kinetics in vivo is critical for interpreting NfL in response to new events where a steady state cannot be assumed, such as acute injury, disease onset or progression, or response to disease-modifying therapies.
Method
We infused human participants with diagnosed primary tauopathies (progressive supranuclear palsy, n = 5; corticobasal syndrome, n = 3; behavioural variant frontotemporal dementia, n = 2) with a stable isotope tracer (13C6-leucine) and collected CSF by lumbar puncture at 4, 14, 20, 60 and 120 days post-labelling. In addition, post-mortem brain tissue from three participants who were infused with the tracer 18, 44 and 50 months earlier were homogenised and biochemically fractionated to separate the soluble and insoluble fraction. NfL was enriched in all samples via immunoprecipitation. The ratio of labelled to unlabelled NfL was measured monitoring proteotypic peptides using established targeted mass spectrometry workflows to quantitate the tracer-to-tracee ratio (TTR).
Result
Analysis of CSF detected low labelling of NfL (0.04 – 0.36% TTR) by 120 days that was comparable to the TTR levels detected in the soluble brain fraction. There was NfL present in the insoluble fraction (2.87% of the total NfL at 18-, 8.87% at 44- and 14.03% at 50-months post-mortem, averaged across several NfL peptides), with different relative abundances of NfL domains between these fractions. Interestingly, the 13C6-labelled NfL signal detected in the insoluble fraction was more abundant, despite a higher recovery of total NfL in the soluble fraction.
Conclusion
NfL turnover in vivo is remarkably slow as it is scarcely captured by 120 days post-labelling. The labelling results from brain tissue suggest that in these cases of primary tauopathies newly-synthesized NfL might be delocalized to a pool of protein of low solubility that does not contribute to NfL levels in CSF. Current experiments are addressing whether newly-synthesized NfL might be sequestered into pathological inclusions.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
